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ABSTRACT
Pancreatic cancer is a highly lethal disease in part due to incomplete tumor 
resection. Targeting by tumor-specific antibodies conjugated with a fluorescent label 
can result in selective labeling of cancer in vivo for surgical navigation. In the present 
study, we describe a patient-derived orthotopic xenograft model of pancreatic cancer 
that recapitulated the disease on a gross and microscopic level, along with physiologic 
clinical manifestations. We additionally show that the use of an anti-CEA antibody 
conjugated to the near-infrared (NIR) fluorescent dye, IRDye800CW, can selectively 
highlight the pancreatic cancer and its metastases in this model with a tumor-to-
background ratio of 3.5 (SEM 0.9). The present results demonstrate the clinical potential 
of this labeling technique for fluorescence-guided surgery of pancreatic cancer.
INTRODUCTION
Pancreatic cancer is a recalcitrant malignancy. 
Complete surgical resection with negative margins 
remains the only curative option. Despite best attempts at 
pre-operative localization through cross sectional imaging 
and intra-operative use of anatomic boundaries, surgeons 
still rely on visual inspection and palpation to determine 
the location of the lesion and set transection margins [1]. 
However, most pancreatic resections are incomplete as 
these visual and tactile cues may miss the tumor margin as 
well as small metastases, especially sub-centimeter lesions 
not detectable by pre-operative imaging modalities and 
this has an impact on patient outcomes [2–5].
Fluorescence guided surgery (FGS) using near-
infrared fluorophores (NIR) conjugated to tumor-specific 
antibodies can assist in visualization of the pancreatic 
cancer and any intra-abdominal metastases that would 
preclude the patient from an invasive and ineffective 
surgical procedure [6]. NIR fluorophores have increased 
tissue depth penetration while limiting light scattering, 
absorbance, and auto-fluorescence [7]. Current FDA 
approved NIR fluorophores include indocyanine green 
and methylene blue. However, these dyes are non-specific. 
Conjugation of NIR-fluorophores to antibodies allows 
selective labeling of tumors and metastases [8].
Studies have been performed with a variety of 
fluorescently labeled antibodies using cell lines over-
expressing the target antigen as a proof of principle [9–12]. 
However, the tumor microenvironment is a heterogenous 
population of cells and the ability of fluorescent antibodies 
to deliver an intense fluorescence signal may be affected. 
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The patient derived orthotopic xenograft (PDOX) models 
are mouse tumor models that use fresh tumor specimen 
obtained from patients at the time of surgery, implanted 
into the corresponding organ of nude mice. They retain 
the heterogeneity of the patient tumor microenvironment 
and better represent the physiology and natural biology of 
the disease, making them a clinically relevant model for 
optical fluorescence tumor imaging [13–15].
In the present study, we use a human pancreatic 
cancer PDOX mouse model that recapitulates the clinical 
behavior of metastatic pancreatic cancer [16]. We 
show that a fluorescent humanized anti-CEA antibody 
specifically labels the primary neoplasm as well as sub-
millimeter satellite lesions that would otherwise be missed 
by bright-light imaging and the naked eye.
RESULTS
Ascites & jaundice in pancreatic cancer PDOX 
mice
The pancreatic cancer PDOX mice in the 
establishment cohort were observed long term for 
evidence of metastases (n = 10). Palpable primary tumors 
appeared in all mice by 6 weeks. Two developed ascites 
as evidenced by abdominal distension and weight gain 
10–12 weeks after surgical orthotopic implantation (SOI) 
(Figure 1A). One mouse also developed jaundice and 
cachexia as evidenced by skin color changes and weight 
loss 14 weeks after SOI (Figure 1B). All mice that did not 
develop ascites showed evidence of cachexia and weight 
loss greater than 20% of initial weight after 14–16 weeks 
and had to be sacrificed. The ten mice evaluated long term 
had diverse metastatic tumors. Supplementary Table 1 
outlines the number and location of these lesions.
Characterization of pancreatic cancer PDOX
Histology of harvested pancreatic cancer PDOX 
orthotopic tumor was that of a high-grade pancreatic 
adenocarcinoma as seen on henatoxylin and eosin-stained 
sections (Figure 2A). Microscopic comparisons between 
the PDOX tumor and slides from the patient tumor showed 
similarities in primary and secondary histo-architecture 
(Figure 2A and 2B).
Higher magnification images of the PDOX tumor 
showed areas invading into normal pancreatic acini 
(Supplementary Figure 1A and 1B). Within the tumor, 
there are intermittent areas of glandular formation and 
mucin production, with diffuse sheets of cancer cells 
prominent (Supplementary Figure 1B). There were 
pancreatic ducts with crowded vesicular nuclei and an 
area of invasion of the myoepithelial layer (Supplementary 
Figure 1C, black arrowhead). Multiple mitotic figures are 
present (Supplementary Figure 1D, red arrows).
Upon necropsy, six mice had grossly visible 
intra-abdominal metastases. Organs were harvested 
and further examined under light microscopy, 
representative images are shown. Two mice had 
microscopically positive metastases in the abdominal 
Figure 1: Pancreatic cancer PDOX model leads to ascites and jaundice in mice. 2/10 mice developed ascites as evidenced by 
abdominal distension and weight gain 10–12 weeks after SOI (A). One mouse also developed jaundice and cachexia as evidenced by skin 
color changes and decreased weight14 weeks after SOI (B).
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wall and spleen (Supplementary Table 1). One mouse 
had a microscopically positive metastasis in the lung. An 
abdominal wall deposit is shown in Figure 3A and 3B. The 
overlying skin and subcutaneous tissue are unremarkable 
(Figure 3A). There were multiple areas of direct tumor 
invasion into the skeletal muscle on higher magnification 
(Figure 3B, black arrows). A peritoneal implant and a 
lymph node are shown in Figure 3C. This peritoneal 
implant is a discrete nodule, detached from surrounding 
abdominal structures. The lymph node does not have 
any evidence of gross or micro-metastases. Small bowel 
tumor implants are shown in Figure 3D. Within the small 
bowel wall, the mucosa is intact, but the tumor invaded 
into both layers of inner circular and outer longitudinal 
layers of the smooth muscle. The small bowel muscularis 
layer is demarcated by the red double headed arrow while 
the invasive front of the tumor is indicated by the blue 
dashed line. There were liver deposits within the hepatic 
capsule (Figure 3E, arrow), but not yet directly invading 
into the adjacent normal appearing hepatic parenchyma. 
Although there were no grossly visible deposits on the 
lung, serial sections showed micro-metastases within the 
pulmonary parenchyma, between two bronchi (Figure 
3F). The spleen showed evidence of both surface deposits 
outside the splenic capsule (Figure 3G, single asterisk), as 
well as direct splenic parenchymal invasion (Figure 3G, 
double asterisk). There was a thick-walled muscular artery 
with tumor cells within the lumen, evidence of vascular 
invasion (Figure 3H). A retroperitoneal implant is shown 
in Figure 3I with invasion of the adjacent adipose tissue.
Western blot of tumor lysates was performed 
using the humanized anti-CEA hT84.66-M5A (hM5A) 
monoclonal antibody as the primary antibody (Figure 4A). 
There was no CEA staining observed with tissue lysate 
from normal pancreatic tissue. Lysates of the pancreatic 
cancer PDOX tissue shows strong CEA staining.
Immunohistochemical staining for CEA using 
hM5A shows strong apical and some cytoplasmic staining 
at the primary tumor (Figure 4B) as well as abdominal 
wall (Figure 4C), small bowel (Figure 4D), and peritoneal 
metastases (Figure 4E).
In-vivo fluorescence imaging of pancreatic 
cancer PDOX
Fluorescence in-vivo imaging using the hM5A 
conjugated to an IR800 fluorophore shows that the antibody-
fluorophore conjugate was able to clearly and specifically 
label the primary pancreatic PDOX tumor (Figure 5A, 
outlined in blue dashed line) as well as metastases over the 
spleen (Figure 5A, outlined in pink fine dashed line) and 
abdominal wall (Figure 5A, purple arrows). There was signal 
present in the liver and the bladder. A bright light image 
of the abdomen shows the primary PDOX tumor (Figure 
5B, outlined in blue dashed lines) and splenic metastases 
(Figure 5B, outlined in pink fine dashed line and arrows). 
A fluorescence intensity heat map is displayed in Figure 
5C, showing the most intense fluorescence signal over the 
primary tumor and abdominal wall metastases.
Fluorescence intensity
Quantification of peak fluorescence signal at 48 
hours was measured and adjusted for the background 
signal of the skin. The average fluorescence intensity after 
48 hours was 286 counts from the tumor, 287 counts from 
the abdominal wall metastases, and 149 counts from the 
liver. The fluorescence signal over the splenic metastases 
was less than that of the tumor and the abdominal wall, but 
the lesions were too small to quantify reliably. The average 
tumor to background ratio was 3.5 (SEM 0.9). The results 
are summarized in Figure 6 ± SEM as error bars.
Figure 2: Concordance between patient histology and pancreatic cancer PDOX. Microscopic comparisons between the 
PDOX tumor (A) and slides from the patient tumor (B) showed consistency in primary and secondary histo-architecture between the two 
specimens. Both were high grade pancreatic adenocarcinoma.
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DISCUSSION
In the present study, we described a PDOX model 
of metastatic pancreatic cancer established from a 
patient surgical specimen and used this PDOX model to 
demonstrate the ability of a humanized anti-CEA antibody 
conjugated to a NIR fluorophore to target the primary 
tumor and even micro-metastases.
While cell line based models can demonstrate 
in-vivo antibody fluorescent labeling, the fluorescent 
signal delivered to the tumor will likely be higher than 
the clinical setting due to the homogeneous nature of 
cell lines and clonal expression of the target antigen. 
Subcutaneous models of patient derived tissue retain the 
heterogeneity of the tumor microenvironment, but they 
rarely induce similar systemic symptoms or metastasize 
[13–15]. In contrast, the pancreatic cancer PDOX model 
induced cachexia, ascites and jaundice, and metastasized 
to the liver, lung, peritoneum, and blood vessels in mice 
(Figure 1). The tumor retained important characteristics 
of the donor tumor at the microscopic level including 
formation glandular architecture and mucin production 
(Figure 2 and Supplementary Figure 1). Further detailed 
necropsy and histology examination showed that this 
tumor replicates the dissemination pattern of metastatic 
pancreatic cancer, with formation of satellite lesions and 
invasion into adjacent structures such as the spleen and 
abdominal wall (Figure 3). The pancreatic cancer PDOX 
model is clinically-relevant model to examine fluorescent 
antibody labeling for FGS.
After confirming that the tumor continued to 
express CEA seen with both western blotting and 
immunohistochemistry (Figure 4), we used this model to 
examine the tumor-targeting efficacy of the humanized 
anti-CEA hM5A antibody conjugated to the IRDye800CW 
NIR fluorophore. Previous work by our group with 
chimeric anti-CEA antibodies and visible wavelength 
dyes have shown the utility of the antibody-fluorophore 
conjugates with improvements in background as the 
fluorophores approached the NIR range [17]. The hM5A-
IR800 construct is unique on a number of levels. First, 
the humanization prevents the formation of human-anti-
chimera antibodies due to the residual murine motifs 
remaining on the probe. In clinical studies using chimeric 
Figure 3: Histology of pancreatic cancer PDOX metastases. Organs from PDOX mice with gross intra-abdominal metastases 
were harvested. There were metastatic deposits seen in the abdominal wall (A, B), within the peritoneum (C), small bowel (D), liver (E), 
lung (F), spleen (G), artery (H), and the retroperitoneum (I). These lesions retained the histoarchitecture of the primary tumor.
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anti-CEA antibodies for radioimmunotherapy imaging 
studies, nearly 30% of patients developed human-anti-
chimera antibodies (NCT02293954, NCT00645060). 
Current M5A-PET imaging studies have not detected any 
human-anti-human antibody immunologic responses thus 
far (unpublished data courtesy of Dr Yazaki). Second, the 
parental hM5A antibody has been shown to be safe in 
patients, showing specificity for the CEA antigen in both 
pancreatic and colon cancers in the studies above. Third, 
the combination with IRDye800CW, a NIR fluorophore 
Figure 4: CEA expression of pancreatic cancer PDOX on western blot and immunohistochemistry. Western blot of tumor 
lysates was performed using hM5A as the primary antibody (A). There was no CEA staining with tissue lysate from normal pancreatic 
tissue. Tumor lysates from the CEA positive and negative pancreatic cancer cell line derived tumors show positive and negative staining 
as expected. Lysates of pancreatic cancer PDOX tissue show strong CEA staining. Immunohistochemistry of Pancreatic Cancer PDOX. 
Immunohistochemical staining for CEA using hM5A showed strong apical and some cytoplasmic staining at the primary tumor (B) as well 
as abdominal wall (C), small bowel (D), and peritoneal implants (E).
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improves tissue penetration compared to visible 
wavelength fluorophores. This is a clinically-relevant 
fluorophore, as a number of FDA approved NIR imaging 
devices designed for indocyanine green at 800 nm can also 
image IRDye800CW, due to spectral overlap [18]. Phase I/
II clinical trials combining cetuximab with IRDye800CW 
have not reported any serious adverse effects with the 
addition of the fluorophore [19, 20].
In-vivo fluorescence imaging of the pancreatic 
cancer PDOX using hM5A-IRDye800CW showed that 
the antibody-fluorophore conjugate was able to selectively 
target and label not only the primary tumor, but also 
highlighted small intra-abdominal metastases that could 
otherwise have been missed with only bright light imaging 
(Figure 5). The fluorescence intensity and contrast, as 
indicated by the tumor-to-background-ratio was adequate 
for delineating the cancerous lesions (Figure 6). However, 
when compared to previous work performed using the 
same hM5A-IR800 and a CEA-positive human pancreatic 
cancer cell line, BxPC3, the pancreatic cancer PDOX 
model showed 8-fold lower overall fluorescence intensity 
values and 4-fold lower contrast at 48 hours [21]. This 
could be due to the heterogeneity of antigen expression in 
a PDOX tumor compared to a uniform antigen expression 
from a more homogenous cell line population. This could 
also be due to the high serum CEA levels with shed 
antigen binding to a majority of the antibody-fluorophore 
conjugate in the serum, leading to a decreased amount of 
the overall probe able to reach the tumor. This possibility 
is supported by the two-fold increased fluorescence values 
at the skin in the pancreatic cancer PDOX mice compared 
to BxPC3 tumor-bearing mice imaged using hM5A-IR800 
at 48 hours. The threshold limit of serum CEA that may 
affect an anti-CEA antibody reaching the tumor surface 
Figure 5: Selective tumor labeling of pancreatic cancer PDOX by hM5A-LICOR800. Optical in-vivo imaging using 
fluorescent M5A-IR800 shows that the antibody-fluorophore conjugate was able to clearly and specifically label the primary pancreatic 
tumor (A, outlined in blue) as well as metastases over the spleen (A, outlined in pink) and abdominal wall (A, purple arrows). There was 
signal present in the liver and the bladder. A bright light image of the abdomen shows the primary tumor (B, outlined in blue dashed lines) 
and splenic metastases (B, outlined in pink and pink arrows). A fluorescence intensity heat map is displayed in (C), showing the most 
intense fluorescence signal over the primary tumor and abdominal wall metastases.
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antigen is unclear. This issue that could possibly be 
addressed in future work by studying the amount of serum 
CEA shed in mouse models using pancreatic cancer cell 
lines as compared to PDOX models. Another possibility 
is to treat with a “priming” dose of unconjugated 
antibody to neutralize the serum antigen, followed up the 
fluorescently-labeled construct.
The metastases in the abdominal wall had similar 
fluorescence intensity compared to the tumor. The splenic 
lesions appear to have lower fluorescence intensity on 
the heat map. However these metastases were too small 
to reliably quantify fluorescence intensity using the 
CRI Maestro software. Metastases such as these can be 
examined under 800 nm fluorescence microscopy in 
future experiments. The reasons for fluorescence intensity 
differences are likely multifactorial: tissue permeability 
and perfusion issues likely play a major role. The probe 
is initially delivered to any tissue with perfusion and it is 
possible that the metastatic lesions have not yet developed 
the pronounced vascular supply of the primary tumor. This 
could lead to restricted probe delivery, decreased antibody-
antigen binding and decreased fluorescence at the 
metastatic lesions. It could be attributed to antigenic shift 
leading to differential antigenic density in the metastatic 
lesions since metastases are further de-differentiated 
It is likely not attributable to tissue depth as the splenic 
metastases were surface lesions.
Fluorescence targeting using hM5A-IR800 produces 
a non-specific signal in the liver and the bladder which has 
been seen in our previous work [21]. Our initial study with 
this probe shows that it washes out to negligible levels in 
48 hours, but it is not an ideal one for detection of liver 
metastases. Other antibody-fluorophores with limited liver 
accumulation would be preferable and those are actively 
under evaluation in our lab at this time.
Despite these issues, the images obtained using 
hM5A-IR800 as compared to bright-light images in the 
pancreatic cancer PDOX model highlight the potential of 
fluorescently-labeled antibodies to visualize pancreatic 
cancer. Pancreatic cancer is a malignancy with a dense 
fibrotic stroma which may necessitate a high fluorogenic 
potential to deliver a targeted signal. Here, the probe was 
able to highlight the tumor and its metastatic lesions. While 
the work showed proof-of-concept feasibility, it was not 
designed to test sensitivity and specificity of the probe. The 
pancreatic cancer PDOX model is an appropriate platform 
for further experiments such as sensitivity and specificity 
testing of antibody-fluorophore conjugates for FGS.
Fluorescent hM5A-IR800 has clinical relevance 
to determine resection boundaries of pancreatic cancer 
for FGS, and detect peritoneal disease during diagnostic 
laparoscopy where radiographically-occult metastases 
can be encountered up to 10% of the time despite the use 
of high resolution computed tomography scans [22]. The 
use of this technology could decrease the rates of positive 
pancreatic margins and increase the rates of detection 
of peritoneal disease. Since these targeted fluorophores 
give information not only about the localization of the 
tumor, but also its antigenic expression, they may indicate 
shifts in antigenic expression after neoadjuvant therapies, 
Further studies will need to be performed to examine the 
changes of fluorescence signal in this setting. 
Humanized anti-CEA antibody conjugated to an 
NIR-fluorophore is a clinically-promising conjugate for 
imaging pancreatic cancers, both at the primary location 
as well as metastases. The hM5A-IR800 probe selectively 
targeted and labeled cancerous lesions in a clinically-
relevant metastatic pancreatic cancer PDOX model. It was 
able to delineate lesions that could otherwise have been 
missed with only bright light visualization.
Figure 6: Fluorescence intensity of pancreatic cancer PDOX labeling by hM5A-IR800. Quantification of peak fluorescence 
signal at 48 hours was measured and adjusted for the background signal at the skin. The average fluorescence intensity after 48 hours was 
286 counts from the tumor, 287 counts from the abdominal wall metastases, and 149 counts from the liver (+/– SEM as error bars).
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MATERIALS AND METHODS
Animal care
Immunocompromised nude nu/nu mice were 
maintained in a barrier facility on high-efficiency 
particulate air (HEPA)-filtered racks at AntiCancer Inc. 
Mice were maintained ad lib on an autoclaved laboratory 
rodent diet (Teckland LM-485; Western Research 
Products, Orange, CA, USA) and kept on a 12 hour light/ 
12 hour dark cycle. All surgical procedures and intravital 
imaging were performed with the animals anesthetized 
by intramuscular injection of an anesthetic cocktail 
composed of ketamine 100 mg/kg (MWI Animal Health, 
Boise, ID, USA), xylazine 10 mg/kg (VWR, Brisbane, 
CA, USA), and acepromazine 3 mg/kg (Sigma, Saint 
Louis, MO, USA). Tumor bearing mice were monitored 
twice a week. All animal studies were conducted in 
accordance with the principles and procedures outlined 
in the NIH Guide for the Care and Use of Animals under 
PHS Assurance Number A3873-1.
Establishment of a patient derived orthotopic 
xenograft mouse model
Samples from pancreatic cancers of patients 
undergoing surgical resection at the University of 
California San Diego (UCSD) Medical Center under an 
Internal Review Board (IRB) approved protocol #090401. 
Patients were consented for tissue collection and research 
by the UCSD Biorepository and Tissue Technology 
Program at their clinic visit prior to surgery. Tumor 
fragments were collected and implanted subcutaneously 
over the flanks of nude mice. Subcutaneous tumors were 
monitored twice a week and allowed to grow for 4–8 
weeks to develop patient derived xenograft mouse models 
(PDX). Once the subcutaneous tumors were large enough 
to supply adequate tumor for orthotopic implantation, 
approximately 7–10 mm, the subcutaneous tumors were 
harvested and surgically engrafted onto the pancreatic 
tail of recipient nude mice using a surgical orthotopic 
implantation (SOI) technique developed for pancreatic 
cancer [16].
The pancreatic cancer PDOX was established from 
a specimen obtained during a liver biopsy of a patient with 
metastatic pancreatic cancer and it was selected for further 
characterization. Pre-operative serum CEA levels in the 
patient were greater than 300 ng/mL. In the establishment 
and observation group (n = 10), orthotopic tumor bearing 
mice were monitored twice weekly until development of 
ascites (n = 2) and/or jaundice (n = 1) as evidenced by 
skin color changes. These mice were then monitored daily 
for signs of pain/distress, impaired mobility, cachexia, 
and sacrificed for clinical indications of morbidity. 
Upon sacrifice, tissue from these mice were collected for 
histology.
Antibody conjugation
The humanized hT84.66-M5A (hM5A) mAb was 
established by grafting the CDR region of the murine 
mT84.66 mAb onto a human anti-p185HER2 antibody 
(Trastuzumab) framework, as previously described [23]. 
Purified hM5A antibody was conjugated with NHS-
IRDye800CW (LI-COR Biosciences, Lincoln, NE, USA) 
at 10-fold molar excess of dye at room temperature for 
1 hour. Absorbance at 280 nm was used to determine 
concentration of the fluorophore-conjugated antibody. 
Final concentration of antibody-dye conjugate was 5.7 mg/
mL. Mass spectrometry was used to determine an average 
of 6 dye molecules per IgG.
Histology
Tumor tissue was removed along with surrounding 
normal tissue at the time of mouse necropsy including 
primary tumor and abdominal metastases. Tissue was 
harvested to confirm pancreatic origin of intra-abdominal 
metastases and to detect sub-clinical lesions. The following 
organs were harvested: primary tumor, pancreas, small 
and large bowel, liver, lung, spleen, abdominal wall, 
abdominal lymph nodes. The tissue was fixed in and 
embedded in paraffin. Tissue blocks were sectioned at 
3 µm and stained with hematoxylin and eosin (H&E) 
per standard protocols. Immunohistochemistry was 
performed per standard protocols. Slides were incubated 
with hM5A as a primary antibody. Goat anti-human 
immunoglobulin horseradish peroxidase labeled antibody 
sc-2453 (Santa Cruz Biotech, Dallas TX, USA) was used 
as a secondary antibody. Horseradish peroxidase was 
visualized by a diaminobenzidine (DAB) chromogenic 
reaction. Light microscopy of slides was performed with 
an Olympus microscope equipped with the Olympus DP27 
camera and CellSens software (Olympus Co, Scientific 
Solutions Group, Waltham, MA, USA). Interpretation of 
the histologic slides was performed by an experienced 
pathologist (BD).
In-vivo fluorescence imaging studies
In the fluorescence imaging group (n = 3), mice 
with pancreatic cancer PDOX were injected intravenously 
with 75 µg of M5A-IR800. Mice were imaged with the 
Maestro CRI imaging system (Perkin Elmer, Waltham, 
MA, USA) 48 hours after injection. Images were acquired 
at the IRDye800CW wavelength (excitation 778 nm, 
emission 800 nm). Fluorescence intensity was quantified 
at the following locations: primary tumor, adjacent truncal 
skin, liver, and satellite lesions. Fluorescence intensity was 
adjusted for background noise by subtracting the peak 
fluorescence intensity at the adjacent truncal skin with 
the peak fluorescence intensity at the primary tumor. The 
tumor-to-background ratio was determined as a ratio of 
Oncotarget37341www.oncotarget.com
peak fluorescence intensity of the primary tumor compared 
to adjacent truncal skin. Fluorescence heat map intensity 
image was created using the Maestro CRI software.
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